Loading
A phase 2 trial of Roginolisib in uveal melanoma, run by iOnctura, active and no longer recruiting.
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma is a phase 2 interventional study registered as NCT06717126 by iOnctura, with 85 participants enrolled, started 2025-02-27 and due to reach its primary completion in 2027-12. Interventions recorded: roginolisib and Investigator choice of standard therapy.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.